Esperion Therapeutics, Inc. (NASDAQ: ESPR) closed its acquisition of Corstasis Therapeutics, Inc. on April 2, 2026, adding the first‑in‑class intranasal loop diuretic Enbumyst to its product line. The deal was structured with an upfront cash payment of $75 million and the potential for up to $180 million in milestone payments, plus future royalty and licensing‑based revenue streams. Financing was secured through a $25 million term loan and a $50 million royalty purchase agreement, allowing Esperion to leverage its existing credit facilities and asset monetization strategy.
The acquisition aligns with Esperion’s Vision 2040, which seeks to broaden its focus beyond lipid‑lowering therapies into cardiometabolic and rare hepatic and renal conditions. By integrating Enbumyst, Esperion gains access to a $4 billion‑plus heart‑failure market and a new revenue stream that complements its NEXLETOL and NEXLIZET products. The company plans to use its established cardiology commercial infrastructure—prescriber relationships, payer engagement, and field execution—to accelerate Enbumyst adoption and create cross‑selling opportunities with its existing portfolio.
Enbumyst is the only FDA‑approved nasal spray loop diuretic, offering a self‑administered alternative to oral and intravenous diuretics that can be difficult to deliver in outpatient settings. The product’s unique delivery platform addresses a clear unmet need for patient‑friendly edema management, positioning Esperion to capture market share in a competitive landscape dominated by oral loop diuretics and IV therapies.
Prior to the acquisition, Esperion reported a Q4 2025 basic EPS of $0.22, missing analyst expectations of $0.26, and a net loss of $40.5 million in Q1 2025. The Q1 2026 earnings miss of $0.22 versus the $0.26 forecast highlights ongoing pricing and cost pressures, but the new product line and financing structure are expected to offset these challenges over the next 12 months. The $75 million upfront payment and milestone structure provide a balanced risk profile, while the royalty monetization reduces immediate cash outlay.
The deal represents a strategic diversification that reduces Esperion’s reliance on its lipid‑lowering franchise and positions the company to capture a sizable share of the heart‑failure market. Cross‑selling synergies with NEXLETOL and NEXLIZET, combined with the patient‑friendly nature of Enbumyst, are expected to drive incremental revenue and strengthen Esperion’s foothold in cardiovascular care. The acquisition also signals management’s confidence in expanding beyond its core product lines, reinforcing the company’s long‑term growth strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.